Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse 21:00:02 17/06/2024 BST 5-day change 1st Jan Change
6.01 USD -2.59% Intraday chart for Emergent BioSolutions Inc. -5.95% +150.42%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Earnings Deluge Continues MT
Fed Decision Eases Investor Anxiety as US Futures Trend Higher in Thursday's Premarket MT
Top Premarket Gainers MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Posts Q1 EPS $0.59 MT
Transcript : Emergent BioSolutions Inc., Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q1 Revenue $300.4M, vs. Street Est of $224.5M MT
Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024 CI
Emergent BioSolutions Inc. Provides Revenue Guidance for the Second Quarter of 2024 CI
Emergent BioSolutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Emergent BioSolutions to lay off about 300 employees RE
Emergent BioSolutions to cut 300 jobs RE
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position CI
Emergent BioSolutions Inc. Enters into A Consent, Waiver and Seventh Amendment to the Amended and Restated Credit Agreement CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise MT
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility MT
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility CI
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade MT
Emergent BioSolutions Shares Drop on S&P Downgrade DJ
North American Morning Briefing : Stock Futures -2- DJ
Chart Emergent BioSolutions Inc.
More charts
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.01 USD
Average target price
5 USD
Spread / Average Target
-16.81%
Consensus
  1. Stock Market
  2. Equities
  3. EBS Stock
  4. News Emergent BioSolutions Inc.
  5. Sector Update: Health Care Stocks Mixed in Late Afternoon
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW